An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65 -Mediated Inherited Retinal Dystrophies in the UK

ConclusionThe results of the model show VN to be a cost-effective use of healthcare resources in the UK at list price. The availability of a commercial discount in the UK (as considered in the NICE appraisal) means that in reality the ICER will be even lower.Plain Language SummaryPlain language summary available for this article.

Source: Advances in Therapy - February 6, 2020 Category: Drugs & Pharmacology Source Type: research